Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
NCT ID: NCT05289492
Last Updated: 2024-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
16 participants
INTERVENTIONAL
2022-05-01
2023-11-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT05560399
Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
NCT01889420
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
NCT05981209
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
NCT03283046
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
NCT03015792
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A: Participants will receive EOS884448
EOS884448 will be administered
EOS884448
EOS884448 will be administered in arm A,B and C
B: Participants will receive EOS884448 and iberdomide
EOS884448 and iberdomide will be administered
EOS884448
EOS884448 will be administered in arm A,B and C
Iberdomide
Iberdomide will be administered in arm B and C
C: Participants will receive EOS884448, iberdomide and dexamethasone
EOS884448, iberdomide and dexamethasone will be administered
EOS884448
EOS884448 will be administered in arm A,B and C
Iberdomide
Iberdomide will be administered in arm B and C
Dexamethasone
Dexamethasone will be administered in arm C
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EOS884448
EOS884448 will be administered in arm A,B and C
Iberdomide
Iberdomide will be administered in arm B and C
Dexamethasone
Dexamethasone will be administered in arm C
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All participants must have received at least 3 prior lines of MM therapy with IMiD, PI and Anti-CD-38, and progressed on their last therapy (prior BCMA targeted therapy allowed).
* All participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0,1or 2.
* All participants must have adequate organ function.
* Females of childbearing potential (FCBP) or male participant must agree to follow contraception requirements.
Exclusion Criteria
* All participants with known auto-immune disease
* All participants with history of life-threatening toxicity related to prior immune therapy.
* All participants with active graft versus host disease after allogeneic stem cell transplantation.
* All participants with active, unstable cardiovascular function.
* All participants with active infection requiring systemic therapy.
* All participants with hypersensitivity to any of the treatments.
* All participants with any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
GlaxoSmithKline
INDUSTRY
iTeos Belgium SA
INDUSTRY
iTeos Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Iteos Clinical Trials
Role: STUDY_DIRECTOR
iTeos Belgium SA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner MD Anderson
Gilbert, Arizona, United States
Eastern Connecticut Hematology & Oncology
Norwich, Connecticut, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
ZNA Cadix
Antwerp, , Belgium
Institut Jules Bordet
Brussels, , Belgium
Universitaire Ziekenhuizen KU Leuven
Leuven, , Belgium
CHU Amiens
Amiens, , France
Centre Hospitalier Universitaire de Nantes
Nantes, , France
APHP Hôpital Saint-Antoine
Paris, , France
CHU de Poitiers
Poitiers, , France
CHU Toulouse
Toulouse, , France
Hospital Fundacion Jimenez Diaz
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TIG-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.